Consensus MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
5.210 ^USD	-6.63%		-10.94%	-8.11%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

Evolution of the Average Target: MannKind Corporation

Evolution of the Target Price: MannKind Corporation

Changes in Analyst Recommendations: MannKind Corporation

ecce618a.J08UBX-i2KIiBtI0okZ2O2_2q35rHyGxGlZ9Sbf8l_s.ayd8fSyWteRzTJF40HREej2mwj0hdxXbKSERLYKXpalmAXxiCuyR9xBJ4g~80324764ad9eec0156476ab28b9af22a

Analysts' recommendations: MannKind Corporation

11-11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
11-11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
13/10/25	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
05/09/25	Oppenheimer Adjusts MannKind Price Target to $15 From $12, Maintains Outperform Rating	MT
26/08/25	RBC Raises Price Target on MannKind to $8 From $7, Keeps Outperform Rating	MT
07/08/25	RBC Cuts Price Target on MannKind to $7 From $8, Keeps Outperform Rating	MT
06/08/25	Biotech firm MannKind's Q2 revenue rises 6%	RE
23/07/25	RBC Cuts Price Target on MannKind to $8 From $10, Keeps Outperform Rating	MT
10/04/25	Mizuho Initiates MannKind at Outperform With $12 Price Target	MT
10/02/25	Wedbush Initiates MannKind at Outperform With $11 Price Target	MT
20/12/24	MannKind Shares Rise After Wells Fargo Begins Coverage	MT
20/12/24	Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target	MT
19/12/24	RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7	MT
14/11/24	Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7	MT
08/11/24	RBC Capital Adjusts Price Target on MannKind to $7 From $5, Maintains Sector Perform Rating	MT
28/08/24	Oppenheimer Adjusts MannKind Price Target to $12 From $10, Maintains Outperform Rating	MT
14/11/23	Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	MT
10/10/23	Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	MT
14/08/23	HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	MT
27/02/23	HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	MT
09/11/22	SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	MT
28/02/22	HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	MT
14/05/21	MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share	MT
05/03/21	MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MANNKIND CORPORATION					+84.47%
	ARGENX SE					+18.83%
	WUXI APPTEC CO., LTD.					+24.54%
	INSMED INCORPORATED					+32.54%
	BIONTECH SE					+26.81%
	WUXI BIOLOGICS (CAYMAN) INC.					+2.93%
	GENMAB A/S					-1.58%
	AKESO, INC.					+42.51%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+12.44%
	SUMMIT THERAPEUTICS INC.					+90.21%
	Average					+33.37%
	Weighted average by Cap.					+24.95%